Health Trials

About this trial

The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Confirmed diagnosis of the respective NHL

If patient is alive: signed written informed consent

For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.

Disqualifiers

No systemic therapy for respective lymphoid malignancy.

Trial design

Treatments tested in this trial

  • Routine care as per site standard.

Treatment groups

2,950 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Locations

1
Praxis für Interdisziplinäre Hämatologie und Onkologie Freiburg im Breisgau Germany

Sponsors and collaborators

iOMEDICO AG

Lead sponsor

Source ClinicalTrials.gov